In Colombia the chronic obstructive pulmonary disease represented the fifth disease with most DALYs for both genders, especially in patients older than 30 years. According to this result we decided to determine the economic cost of the chronic obstructive pulmonary disease in Colombia from the third-payer and patient perspectives for year 2011. To calculate the monetary costs, we assumed that a treatment was provided to every patient reported on the system according to CIE-10: J440, J441, J448 y J449, and the study of Perez et al. (2008) and from the SOAT fare manual 2011 reported by the government. We used the official SISPRO data to get information regarding the number of visits per patient who had a diagnosis of chronic obstructive pulmonary disease. To obtain the third-payer cost we multiplied the treatment cost for each patient by the total number of registers. We calculated from the patient´s perspective the lost output as a result of a reduction of productivity due to chronic obstructive pulmonary disease, using the DALYs adjusted by life expectancy, multiplied by the 2011 current GDP divided by the working-age population. The total Economic impact for 2011 was USD 1.543.655.654. This is the result of adding the third-payer cost of USD 1.533.564.250 plus the patient cost of USD 10.091.403. The cost of chronic obstructive pulmonary disease represents 0.46% of 2011 current GDP, this means that on average there is an expenditure of USD 33.53 for each Colombian citizen to prevent the disease. Those numbers shows the importance to generate permanent public policies to improve the Colombians´ health.